NCT03559790Unknown不适用
Treatment Efficacy and Safety of Tenofovir Alafenamide (TAF) Switch Therapy in Patients Who Have Been Treated With Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B: a Real Life Multicenter Cohort Study in Korea
适应症
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Complete Virological response
研究概览
简要总结
Recent TAF has introduced to have more safe profiles than TDF in clinical trials. Especially, TDF has the renal safety issue in high risk group including HIV, decompensated cirrhosis (ascites), uncontrolled DM etc.
However, there is no available cohort data for treatment efficacy and safety in TDF-TAF switch therapy in treatment-naïve chronic hepatitis B.
The aim of this study is to evaluate safety and efficacy of TAF switch therapy in patients with chronic hepatitis B who have been treated with TDF.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- •Adult male and non-pregnant, non-lactating female subjects, 18 years of age and older, based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (unless surgically sterile or greater than 2 years post-menopausal).
- •Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months)
- •Previous TDF naïve treatment (more than 96 weeks) baseline status including chronic hepatitis B with the following:
- •HBeAg-positive and HBeAb negative at Screening
- •Screening HBV DNA ≥ 1x 105 copies/mL
- •Screening serum ALT level ≥2×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- •HBeAg-negative and HBeAb positive at Screening
- •Screening HBV DNA ≥ 1x 104 copies/mL
- •Screening serum ALT level ≥2×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- •Cirrhosis at Screening
- •Screening HBV DNA ≥ 1x 104 copies/mL regardless of HBeAg status
- •Treatment naïve subjects defined as no history of antiviral therapy or < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue, including lamivudine or adefovir, clevudine, telbivudine, entecavir
- •The decision is made by the provider and patient to switch from TDF to TAF prior to discussion of the study of enrollment
- •Following the decision to switch therapy, signed written informed consent after being instructed about the objective and procedure of the clinical study
- •Must be willing and able to comply with all study requirements
排除标准
- •Subjects who meet any of the following exclusion criteria are not to be enrolled in the study.
- •Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.
- •Co-infection with HCV, HIV
- •Evidence of hepatocellular carcinoma (e.g. α-fetoprotein> 50 ng/mL or as evidenced by recent ultrasound or other standard of care measure)
- •Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible
- •Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
- •Currently receiving therapy with cytotoxic agent, nephrotoxic agents, or agents capable of modifying renal excretion
- •Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
结局指标
主要结局
Complete Virological response
时间窗: at Week 96.
Portion of subjects with plasma HBV DNA levels below 116 copies/mL
Incidence of of elevation of serum creatinine as a measure of renal safety
时间窗: at Week 96
Incidence of elevation of serum creatinine (\>0.5mg/dL) from baseline creatinine
Incidence of osteopenia and osteoporosis as a measure of bone safety
时间窗: at Week 96
Incidence of osteopenia and osteoporosis according to Bone Mineral Density
次要结局
- Biochemical response(at Week 48 and 96)
- Serologic response(at Week 48 and 96)
- Incidence of treatment-emergent adverse events(at Week 48 and 96)
研究者
Myeong Jun Song
Associate Professor
The Catholic University of Korea
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)IdesHepatitis B, ChronicNCT04201808New Discovery LLC100
招募中
4 期
Tenofovir Alafenamide in HBV Related Decompensated LiverHBVNCT04683341Kaohsiung Medical University Chung-Ho Memorial Hospital100
招募中
不适用
Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis.Chronic hepatitis B and cirrhosisJPRN-UMIN000034362ippon Medical Chiba Hokusoh Hospital500
进行中（未招募）
1 期
Safety of tenofovir alafenamide (TAF) in patients who developed kidney toxicity while receiving tenofovir disoproxil fumarate (TDF)HIV infectionMedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003345-29-GBKings College Hospital NHS Foundation Trust40
Unknown
4 期
Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)Hepatitis B, ChronicMother to Child TransmissionNCT05177926Nanfang Hospital, Southern Medical University330